From relapse to survival: real-world clinical impact of a multimodal approach in first-time recurrent glioblastoma : FROST: multimodal treatment for GBM recurrence.

Fiche publication

Date publication

juin 2026

Journal

Journal of neuro-oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr NOEL Georges , Dr SCHOTT Roland , Dr SOMME Laura , Dr CEBULA Hélène

Tous les auteurs :
Barbe-Richaud JB, Cebula H, Todeschi J, Santin MDN, Baloglu S, Schott R, Cotton M, Blouet A, Bobin M, Noël G, Somme L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42334687

Résumé

Glioblastoma (GBM) is the most common malignant brain tumor in adults. The current treatment is surgery followed by chemoradiotherapy (CRT) and adjuvant temozolomide (TMZ). Three out of four patients experience recurrence within the year following diagnosis. The management of first GBM recurrence remains challenging with no standardized guidelines. This study aimed to evaluate multimodal strategies combining systemic therapy, radiotherapy, surgery as a potential promising approach to enhance patient outcomes.